Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Blood - 6 Aug 2015

Patel Keyur P, Newberry Kate J, Luthra Rajyalakshmi, Jabbour Elias, Pierce Sherry, Cortes Jorge, Singh Rajesh, Mehrotra Meenakshi, Routbort Mark J, Luthra Madan, Manshouri Taghi, Santos Fabio P, Kantarjian Hagop, Verstovsek Srdan

Abstract excerpt

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes recurrently mutated in hematologic malignancies in a cohort of patients with MF who were treated with ruxolitinib in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Receptors, Thrombopoietin

Share to Spleen

Source

Open in PubMed Open full text

Identifiers

PMID: 26124496
DOI: 10.1182/blood-2015-03-633404
PMCID: PMC4528066

Genes

JAK2
CALR
ASXL1
GATA2
KRAS
MPL
NRAS
PTPN11
RUNX1
TET2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.PMID 26124496Read ↗

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisSemantic proximity Read ↗

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].Semantic proximity Read ↗

Momelotinib therapy for myelofibrosis: a 7-year follow-up.Semantic proximity Read ↗

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.Semantic proximity Read ↗

New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapySemantic proximity Read ↗

Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.